向治疗改善了细胞功能障碍,动脉和发作易感性在一个渐进性肌性的模型
Huijie Feng1, Jerome Clatot2, Keisuke Kaneko3
1Division of Neurology, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
Cell reports. Medicine
|January 24, 2024
概括
一项新的研究确定了对7型渐进性肌性 (EPM7) 的潜在治疗方法. 通过AUT00206增强Kv3通道活动,在小鼠模型中改善了运动功能和减少了发作.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 进展性肌肉性型7 (EPM7) 是一种由KCNC1基因变异引起的严重神经疾病,导致进展性肌肉性,和性衰竭.
- KCNC1基因编码Kv3.1通道子单元,这对于高频神经元发射至关重要. 功能丧失的变体会损害神经元的刺激性,从而导致EPM7的病变.
研究的目的:
- 调查EPM7.7的细胞和电路基础.
- 为了评估增强Kv3通道活性用于EPM7治疗的治疗潜力.
主要方法:
- 生成一个KCNC1-p.Arg320His/+小鼠模型,显示核心EPM7特征.
- 评估小脑和新皮质中Kv3.1表达神经元功能的评估.
- 在小鼠模型中,对Kv3特异性正模拟器 (AUT00206) 对神经元激发,运动功能和发作易感性的影响进行评估.
主要成果:
- 在KCNC1-p.Arg320His/+小鼠模型中,呈现出渐进的动力衰竭和发作易感性.
- 在表达Kv3.1的小脑颗粒细胞和新皮层内部神经元中观察到异常,与Kv3通道功能障碍相一致.
- 在受影响的小鼠中,AUT00206选择性地增强了Kv3.1神经元发射频率,并改善了运动缺陷和发作易感性.
结论:
- 这项研究阐明了EPM7.7背后的细胞和电路机制.
- 以AUT00206为例的Kv3阳性调节器在EPM7治疗中显示出显著的治疗潜力.
相关概念视频
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
303
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
303
Antiepileptic Drugs: Glutamate Antagonists
359
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
359
Antiepileptic Drugs: GABAergic Pathway Potentiators
403
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
403
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Arteries of the Lower Limbs
190
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
190
Antiepileptic Drugs: Potassium Channel Activators
183
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
183


